Despite the tremendous increase in understanding of basic cancer mechanisms and potential targets there has only been a moderate increase in effective new therapies to treat cancer.  The Gray Laboratory seeks to develop first-in-class chemical inhibitors that can be used to pharmacologically validate new potential targets to treat cancer and other diseases.